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Fine and ultrafine particulate air pollution
appears to be associated with important
adverse health consequences. A number of
observational population-based epidemio-
logic studies indicate a strong relationship
between mortality and ambient air pollu-
tion from particulates less than 2.5 pm in
size (1-9). Animal studies offine and ultra-
fine particulate matter, including experi-
mental studies with concentrated ambient
air samples, have found these exposures to
be acutely toxic, supporting the epidemio-
logic association in humans (10-12).
Despite this strong evidence linking fine
and ultrafine particle inhalation with
adverse health effects, the mechanisms by
which particle toxicity may be exerted are
poorly understood. Indeed, the extent to
which particle chemical composition itself
determines toxicity, as opposed to size and
other generic physical characteristics ofpar-
ticulates, remains unclear. To date there has
been no controlled human experimental
exposure model of fine and ultrafine parti-
cle inhalation effects.
Metal oxides comprise an important
group ofparticulate pollutants. Forexample,
zinc, magnesium, iron, and vanadium
oxides are components offly ash, a product
of fossil fuel combustion. Exposure to fly
ash, which occurs in avariety ofoccupation-
al and environmental settings, has been
linked with lung function decline including
obstructive lung disease (13) and interstitial
fibrosis (14). Further, inhalation of zinc
oxide fume in high concentration is a well-
established cause ofthe occupational flulike
syndrome metal fume fever (15-14. We
have previously reported a pulmonary
inflammatory cellular response in healthy
humans following experimental inhalation-
al exposure to zinc oxide fume (18-20).
To determine whether this represents a
specific chemical effect of zinc oxide or
rather a potentially generic response to fine
and ultrafine metal oxide particles, we car-
ried out a series of experimental human
exposures to purified magnesium oxide
fume. The principal goal of this investiga-
tion was to determine whether magnesium
oxide inhalation invokes a similar response
to the inflammatory cellular influx we have
observed following zinc oxide fume expo-
sure. Wehypothesized thatabsenceofsuch a
response, despite ahigh fume exposure level,
would argue against a generic particulate
response driven solelybyparticulate size and
numberofparticles permilligram inhaled.
Material and Methods
Study design overview. We exposed six nor-
mal volunteer subjects to inhaled purified
magnesium oxide particles. We produced
metal oxide fume with a furnace system
under controlled conditions and quantified
cumulative magnesium oxide dose for each
exposure. We assessed partide size and parti-
cle shape by cascade impactor analysis and
scanning electron microscopy. We analyzed
pulmonary inflammatory cell and cytokine
responses 20 hr postexposure by analysis of
bronchoalveolar lavage (BAL) fluid and we
compared these findings with paired control
BAL samples in the same six subjects
obtained without prior magnesium oxide
exposure. We also compared peripheral
blood neutrophil and pulmonary function
18 hr postexposure with baseline values. The
investigation was approved by the University
ofCalifornia, San Francisco, Committee on
Human Research.
Studysubjets. The age, sex, andsmoking
status for each of the six study subjects are
presented in Table 1; we studied both smok-
ers and nonsmokers. None ofthe volunteers
had any history ofoccupational exposure to
magnesium oxide and none reported any his-
toryofchronic oracutelungdisease.
Magnesium oxidefiumeexosure. We pro-
duced controlled quantities offreshly generat-
ed purified magnesium oxide fume utilizing a
furnace system design originally developed by
McCarthyandcolleagues (21), whichwe later
used in human zinc oxide studies (20). We
assessed fumepartide sizebycascade impactor
analysis. We used a micro-orifice uniform
deposit impactor (MOUDI), model no. 110,
with an operation flow rate of30 I/min (MSP
Corporation, Minneapolis, MN). The
MOUDI cut points were inlet cut point, 18
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pm; stages 1-10 (in pm), 10, 5.6, 3.2, 1.8,
1.0, 0.56, 0.32, 0.18, 0.1, 0.056. Asshown in
Figure 1, byweight, over 98% offume parti-
cles were fine or ultrafine and 98.6% were
less than 1.8 pm in diameter. The greatest
percentage (42.0%) of particles by weight
were between 0.1 and 0.18 pm in diameter;
28.6% ofpartides were ultrafine (<0.1 pm in
diameter). The total concentration during
partide size sampling was 90.6 mg/m3. Also
shown in Figure 1, for comparison, is the
partide size distribution for zinc oxide parti-
cles generated by the same furnace system
and used in a previously published experi-
mental inhalation investigation (20). Fume
partides are shown in the scanning electron
micrograph (Fig. 2).
We quantified magnesium concentration
for each experimental exposure bysampling a
known volume filtered through a cellulose
acetate membrane (0.22 pmpore), whichwas
analyzed for metallic magnesium by induc-
tively coupled plasma atomic emission (D &
M Laboratories, Petaluma, CA, and Data
Chem Laboratories, Cincinnati, OH). We
carried out exposures over a range ofmagne-
sium oxide concentrations (Table 2). The
median magnesium concentration (range)
was 133.0 mg/m3 (5.8-230.0 mg/m3). We
varied exposure time in order to produce a
range of cumulative exposures; exposure
duration was determined prior to exposure.
We calculated cumulative exposure levels as
the cross-product of the concentration of
magnesium oxide, measured as metallic mag-
nesium in milligrams per cubic meter, times
the duration of the inhalation exposure
expressed in minutes (min x mg/m3).
Cumulative magnesium exposure (Table 2)
ranged from 261 to 6,435 min x mg/mi3.
Subjects inhaled magnesium oxide fumewith
medical-grade air through a mouth-breathing
facemask. Allsubjects completed an exposure
in full without discomfort or difficulty.
Subjects were asked to record theirbodytem-
perature during the evening following the
afternoon exposure and to document any
symptoms including flulike symptoms of
myalgias, fatigue, andrigors.
Pulmonaryfunction testing. Baseline
(preexposure) pulmonary function testing
was performed in the early afternoon, and
18-hr (postexposure) pulmonary function
testing was done the next morning.
Pulmonary function testing was conducted
with the subject in the sitting position. We
measured forced expiratory volume in 1 sec
(FEV1) using a rolling seal spirometer
according to American Thoracic Society
standards (22). Maximal flow-volume
curves were measured byanalyzing flowand
volume signals with the rolling seal spirom-
eter. We measured total lung capacity
(TLC) by the single-breath helium dilution
method (23), and we measured diffusing
capacity (DLCO) by the single-breath
method ofOgilvie et al. (24).
Peripheral bloodpolymorphonuclear
leukocyte concentration. Complete blood
counts and differentials were obtained at
baseline (preexposure) and at 18 hr postex-
posure to determine peripheral blood poly-
morphonuclear leukocyte concentrations.
Blood counts and differentials were per-
formed in the clinical laboratory of the
University of California, San Francisco
(USCF) Medical Center.
Bronchoscopy and bronchoalveolar
lavage. Each subject underwent two BAL
studies: a postexposure lavage conducted 20
hr after magnesium oxide fume exposure
and a control lavage following exposure to
medical-grade air. An interval ofat least 28
days separated the postexposure and control
lavages. Bronchoscopy included routine
z~~~~ .IJs diEii 6s|
Table 1. Age, sex, and smoking status of study
subjects
Years
since
Age Smoking quitting
Subject (years) Sex status smoking
1 43 Male Never NA
2 21 Female Never NA
3 31 Male Never NA
4 39 Male Former 9
5 40 Male Former 4
6 33 Female Former 9
NA, notapplicable.
Mean age ± standard deviation =34.5 ± 8.0.
50
40
Figure 2. Magnesium oxide particles (A) and zinc
oxide particles (B) on polycarbonate membrane
with 0.015 pm pores. Bar at bottom right of pho-
tomicrograph represents 1 pm.
>3.2 0.32-3.2 0.18-0.32 0.1-0.18 0.056-0.1 <0.056
Particle diametercutoff(gm)
Figure 1. Diameters of furnace-generated magnesium oxide particles compared with those of zinc oxide
particles. Particle size distribution was determined by micro-orifice uniform deposit impactor analysis.
The total magnesium concentration during sampling was 90.6 mg/m3. The total zinc concentration was 6.3
mg/m3. See also Kuschner et al. (20).
Table2 Magnesium oxidefume exposure charac-
teristics
Magnesium Cumulabve
fume Exposure magnesium
concentraton bme dose
Subject (mg/m3) (min) (min xmg/m3)
1 5.8 45 261
2 230 15 3,450
3 210 20 4,200
4 123 45 5,535
5 110 45 4,950
6 143 45 6,435
Mean ±SD 137.0± 80.2 35.8± 14.3 4,138.5±2,163.1
SD, standard deviaton. The median fume concentra-
ton was 133mg/m3.
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atropine premedication and topical anesthe-
sia. A flexible fiberoptic bronchoscope
(Pentax FB-19D; Pentax Precision
Instrument Corporation, Orangeburg, NY)
was wedged in a segmental airway in the
right middle lobe, and BAL was performed
by instilling four 50-ml boluses of370C iso-
tonic saline and applying gentle suction
until no further collection was noted. The
BAL was collected on ice. The mean per-
centage ± standard error (SE) of instilled
BAL fluid recovered was 70.0 ± 3.1% in the
postexposure bronchoscopies and 70.1 ±
2.4% in control BAL studies (p = 0.8). BAL
fluid was pooled but was not gauze filtered.
We performed cell counts using a standard
hemocytometer and differential counts after
5-min cytocentrifugation at 1,000 rpm and
May-Grunwald-Giemsa staining.
Cytokine andprotein determinations.
BAL fluid supernatant was stored at -70°C
for subsequent cytokine analysis. We quan-
tified concentrations of tumor necrosis fac-
tor-ca (TNF), interleukin (IL)-1 3, IL-6,
and IL-8 in BAL supernatant by immun-
odetection with ELISA (R&D Systems,
Minneapolis, MN). Each assay uses a quan-
titative immunometric sandwich enzyme
technique, which we have described else-
where (20). The lower limits ofdetection of
the kits (supplier's data) were as follows:
TNF, 0.085 pg/ml; IL-1, 0.083 pg/ml; IL-
6, 0.080 pg/ml; and IL-8, 3.0 pg/ml.
Nondetectable observations were assigned a
value one-half that of the lower detection
limit in later statistical analyses. The
cytokines analyzed were above the lower
limit of detection in all BAL specimens
except for TNF in three cases (one subject
both postcontrol and postexposure and one
additional subject postexposure only) and
IL-8 in two subjects (both postexposure).
We determined BAL supernatant total pro-
tein concentrations using a commercially
available colorimetric assay (Bio-Rad
Laboratories, Hercules, CA).
Statistical analyses. We used the SAS
standard statistical package for data analysis
Table 3. Pulmonary function: 18 hr postexposure
baseline difference
Pulmonary
function measure
FEV1 (liters)
TLC (liters)
DLCO (ml/min/mm Hg)
Mean ± SD
postexposure
baseline difference*
0.0 ± 0.1
0.1 ±0.2
0.9 ± 1.5
Abbreviations: FEV1, forced expiratory volume in 1
sec; TLC, total lung capacity; DLCO, diffusing
capacityfor CO; SD, standard deviation.
Baseline spirometry was performed in the after-
noon; 18-hr spirometry was performed thefollowing
morning.
*p>0.20 for all differences.
(SAS Institute Inc., Cary, NC). We com-
pared by matched paired t-test: baseline
with postexposure spirometry; baseline with
postexposure peripheral leukocyte counts;
and control with postexposure BAL cell and
supernatant cytokine concentrations.
Results
Symptoms, pulmonary function, and
peripheral bloodpolymorphonuclear leuko-
cyte concentrations. None of the subjects
documented a fever or reported symptoms
postexposure consistent with classic metal
fume fever (myalgia, malaise, headache, or
respiratory complaints). As shown in Table
3, there was no overall postexposure fall in
pulmonary function; slight increases in TLC
(mean increase of100 cc) and DLCO (mean
increase of 0.9 ml/min/mm Hg) were not
statistically significant. There was a mean
decrease ofperipheral blood polymorphonu-
clear leukocyte concentrations postexposure
of 1.1 x 10-3 ± 1.0 x 10-3 (SE)/mm3 com-
pared with baseline, which was also not sta-
tisticallysignificant (p>0.3).
Bronchoalveolar lavage cells and
cytokines. Mean BAL constituent concentra-
tions postexposure and control are shown in
Table4. Overall, therewere nostatisticallysig-
nificant differences in concentrations of BAL
neutrophils, macrophages, lymphocytes, or
protein between postexposure studies and
paired control values, nor any statistically sig-
nificant postexposure increases in concentra-
tions ofany ofthe proinflammatory cytokines
westudied (IL-1, IL-6, IL-8, andTNF).
Discussion
Inhalation of fine and ultrafine particulate
magnesium oxide did not result in a symp-
tomatic response or in any meaningful
changes in lung function or in BAL concen-
trations of proinflammatory cells or
cytokines at 20-hr follow-up. What might
explain the lack ofa pulmonary or systemic
response following exposure to concentra-
tions ofparticulates as high as 230 mg/mi3?
Although it is certainly possible that the
particle exposure concentrations used in
this investigation were simply too low to
result in a detectable clinical response, this
would be inconsistent with ambient air pol-
lution data. Untoward health effects have
been associated with short-term particulate
exposure in concentrations several orders of
magnitude below those to which subjects in
this study were exposed, in the microgram
per cubic meter range. (1-9,25).
Particle size and dimension can be
important determinants of toxicity, both
because of delivered dose and through
other morphologic mechanisms. It is possi-
ble that particles generated by our furnace
system were different in size or shape from
particles which, in other settings, have been
linked with adverse health effects. In gener-
al, however, fine particles (diameters <2.5
pm) are thought to present the greatest
health concern because they most easily
enter the alveolar air space and because
they may deliver more hits, or particles, per
mass delivered. In our model, the vast
majority of the furnace-generated particles
were within respirable range and 98% were
less than 1.8 pm. This would suggest that
particle size and number per milligram, by
themselves, do not provide a simple expla-
nation for the lack of a response effect in
our study. We cannot easily exclude poten-
tial effects of morphologic characteristics
related to particle surface interactions.
It is possible that the follow-up time
was either too early or too late to detect
inflammatory changes in BAL. Our prior
experience with zinc oxide, exposure to
which is clearly proinflammatory, however,
showed that 20 hr is an excellent time point
to detect proinflammatorycytokine and cel-
lular responses in the pulmonary microenvi-
ronment (18-20). Moreover, this follow-up
time point is appropriate in view of the
known kinetics ofthe cytokines studied.
There were no significant methodologi-
cal differences in this study compared with
Table 4. Mean BAL constituents: postexposure-control paired analysis (n=6)
Control Postexposure
BAL constituent (mean ± SD) (mean ± SD) p-Value
Cells (103/ml)
Macrophages 194.7 ± 79.7 150.3 ± 69.5 0.12
Neutrophilsa 2.3 ± 1.6 2.1 ± 1.2 >0.5
Lymphocytes 14.8 ± 10.9 7.9 ± 6.0 0.11
Total protein pg/ml 118.5 ± 68 56.5 ± 22.6 >0.7
Cytokines (pg/mI)
TNF 0.3 ± 0.3 0.3 ± 0.2 >0.7
IL-1 0.1 ± 0.7 0.2 ± 0.7 >0.5
IL-6 2.1 ± 1.0 1.7 ± 0.8 >0.4
IL-8 14.3 ± 10.7 6.7 ± 4.2 0.20
Abbreviations: BAL, bronchoalveolar lavage; SD, standard deviation; TNF, tumor necrosis factor a; IL,
interleukin. Postexposure BALwas performed 18-20 hr aftermagnesium oxide fume exposure.
aNeutrophils as a percent oftotal BAL cells = 1.5 ± 1.0% postexposure versus 1.1 ± 0.9% control (p =0.27).
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our previously reported study of pul-
monary responses 20 hr after zinc exposure
(20) except, of course, for the chemical
composition of the particles studied (zinc
oxide vs. magnesium oxide). In marked
contrast with the benign response to mag-
nesium oxide that we observed in this
investigation, we previously found that
purified ultrafine zinc oxide particle expo-
sure results in dose-dependent increases in
BAL neutrophils, IL-8, and TNF (20). We
used protocols that were essentially identi-
cal in the two investigations. We utilized
the same specially adapted furnace system
capable of producing freshly generated
purified fume in both investigations.
Furnace-generated metal oxide particles
were well within respirable range and were
predominantly under 1 pm in diameter in
both studies. Insufficient cumulative dose
would not appear to explain the benign
response to magnesium compared with
zinc. Indeed, mean cumulative magnesium
dose (± SD) in this investigation, 4,138 ±
2,163 min x mg/m3, was markedly greater
than the mean cumulative zinc dose in our
previous study, 537 ± 232 min x mg/m3.
The outcome measures we studied in the
previous investigations, especially BAL cells
and proinflammatory cytokines, were suffi-
ciently sensitive to detect an inflammatory
response, even with the small subject num-
bers and briefexposures employed.
Our findings would suggest that high-
dose exposure to magnesium oxide fume
may not necessarily be acutely toxic.
Further, our findings argue against the
hypothesis that adverse health effects are
attributable to a generic particle exposure
effect. That is, the chemical composition of
a particle, in addition to its physical proper-
ties and exposure dose, appears to have a
relevant influence on inhalant toxicology.
Health effects are not strictly a function of
particle size and number.
We would not argue that magnesium
oxide inhalation is benign under all circum-
stances. Approximately 70 years ago,
Drinker and Drinker observed adverse
effects in both animal and human exposures
to magnesium oxide fume (26,27). These
effects included a metal fume feverlike
response in humans (maximum 580 mg/m3)
(27). Indeed, these are the only other con-
trolled human exposures to magnesium
oxide reported in the medical literature. In
1983, Hartmann et al. (28) reported that
seven workers in a foundry developed fever
following the introduction of a new found-
ing technique that led to magnesium oxide
fume exposure. Modification ofthe produc-
tion system, with reduction of magnesium
oxide fume generation, was associated with
cessation of febrile episodes among workers.
However, no industrial hygiene data were
provided to quantify exposure levels. In
1992, Takac (29) reported morphologic
changes in the microstructure of organs,
including lungs, ofanimals exposed to mag-
nesite waste containing largely magnesium
oxide. Rats and rabbits were used to biologi-
cally monitor the accumulation and effects of
inhaling air contaminated by the magnesite
industry in two locations in Czechoslovakia.
Study animals were exposed to contaminated
air for 6 months. Findings included alter-
ations in ciliary length, the presence of
Curshman's spirals in smears of pulmonary
lavages, and minor goblet cell abnormalities.
Again, however, no industrial hygiene data
were provided to quantifyexposure levels.
In summary, we found no evidence of
any pulmonary inflammatory responses fol-
lowing short-term fine and ultrafine particle
inhalation to high concentrations ofmagne-
sium oxide. Based on our previous experi-
ence with zinc oxide, we cannot explain this
lack of response by insufficient exposure,
insensitive measures of response, or small
study size. This investigation suggests that
the toxicology ofmetal oxide particles is not
determined simply by particle size charac-
teristics alone (i.e., the number of particles
per milligram inhaled). Hypotheses of air
pollution effects associated with inhalation
offine particles (<2.5 pm diameter) should
heavilyweigh chemical-specific mechanisms
that may modify the dose response depend-
ing on the particle inhaled.
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